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Abstract: The mevalonate pathway, crucial for cholesterol synthesis, plays a key role in 
multiple cellular processes. Deregulation of this pathway is also correlated with diminished 
protein prenylation, an important post-translational modification necessary to localize 
certain proteins, such as small GTPases, to membranes. Mevalonate pathway blockade has 
been linked to mitochondrial dysfunction: especially involving lower mitochondrial 
membrane potential and increased release of pro-apoptotic factors in cytosol. Furthermore a 
severe reduction of protein prenylation has also been associated with defective autophagy, 
possibly causing inflammasome activation and subsequent cell death. So, it is tempting to 
hypothesize a mechanism in which defective autophagy fails to remove damaged 
mitochondria, resulting in increased cell death. This mechanism could play a significant role 
in Mevalonate Kinase Deficiency, an autoinflammatory disease characterized by a defect in 
Mevalonate Kinase, a key enzyme of the mevalonate pathway. Patients carrying mutations 
in the MVK gene, encoding this enzyme, show increased inflammation and lower protein 
prenylation levels. This review aims at analysing the correlation between mevalonate 
pathway defects, mitochondrial dysfunction and defective autophagy, as well as inflammation, 
using Mevalonate Kinase Deficiency as a model to clarify the current pathogenetic 
hypothesis as the basis of the disease. 
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1. Mevalonate Pathway 
The mevalonate pathway, fundamental for cholesterol synthesis, is one of the most important 
metabolic networks in the cell; it provides essential cell constituents, such as cholesterol, and some of 
its branches produce key metabolites, such as geranylgeranyl pyrophosphate and farnesyl pyrophosphate, 
necessary for normal cell metabolism. 
The first step of the mevalonate pathway is the synthesis of 3-hydroxy-3-methylglutaryl-CoA  
(HMG-CoA) from three molecules of acetyl-CoA, firstly by a condensation reaction forming 
acetoacetyl-CoA through acetoacetyl-CoA thiolase (EC 2.3.1.9) and subsequently through a second 
condensation between acetoacetyl-CoA and a third acetyl-CoA molecule catalysed by HMG-CoA 
synthase (EC 2.3.3.10) (Figure 1a, 1). In the second step, HMG-CoA is reduced to mevalonate acid by 
NADPH, a reaction catalysed by the HMG-CoA reductase (HMGR) enzyme (EC 1.1.1.88 and  
EC 1.1.1.34). HMGR is the rate-limiting enzyme for the mevalonate pathway and is one of the most finely 
regulated enzymes [1]. Regulation begins at the transcriptional level; if cholesterol or other sterol 
isoprenoids are in shortage, sterol regulatory element binding proteins (SREBP) are activated and they 
bind to sterol regulatory elements (SREs) present on the HMGR promoter, increasing its transcription [2,3]. 
Cholesterol also regulates the degradation of HMGR, promoting its association with gp78, an ubiquitin-E3 
ligase that directs the enzyme towards proteasome 26s. HMGR is also regulated at the post-translational 
level, by phosphorylation mediated through AMP-activated protein kinase (AMPK). This enzyme is 
sensitive to the AMP:ATP ratio, and is activated by increased AMP concentration, thus in casea of 
metabolic stress, it deactivates HMGR, reducing cellular metabolism [4] (Figure 1a, 2). 
The third key enzyme of the mevalonate pathway is the one responsible for converting mevalonic 
acid into mevalonate-5-phosphate, a key pathway intermediate. Mevalonate kinase (EC 2.7.1.36) 
(MVK) catalyses this conversion, using ATP as a phosphate donor and energy source. Furthermore, this 
enzyme is finely regulated, firstly at transcriptional level in a similar manner of HMGR: SREs are present 
at the MVK promoter and increases its transcription upon cholesterol shortage [5]. In addition,  
MVK presents feedback inhibition from some of the mevalonate pathway substrates, specifically 
geranylgeranyl pyrophosphate and farnesyl pyrophosphate, demonstrating that non-sterol isoprenoid 
could have a key role in regulation of this enzyme [6] (Figure 1a, 3). 
In the fourth step of the mevalonate pathway, Mevalonate-5-phosphate is then converted into 
mevalonate-5-pyrophosphate by phosphomevalonate kinase (EC 2.7.4.2), using again ATP as phosphate 
and energy donor. Differently from MVK, this enzyme does not present feedback inhibition from its 
products [6]. However, various compounds were recently found to be inhibitors for this enzyme, suggesting 
novel mechanisms to inhibit the mevalonate pathway [7] and more interestingly, phosphomevalonate 
kinase appears also to be regulated by cholesterol shortage, as for mevalonate kinase and HMGR [8]. 
Indeed, cholesterol shortage induces increases in all the three first enzymes of the mevalonate pathway, 
thus guaranteeing a continued supply of this key membrane component (Figure 1a, 4). 
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Figure 1. Schematic representation of the mevalonate pathway divided into: (a) The 
mevalonate pathway that produces mevalonate 5-PP and then isppententenyl 5-PP; (b) The 
cholesterol pathway that produces cholesterol, which in turn induces the formation of steroid 
hormones, vitamin D and bile acids; and (c) The non-cholesterol pathway important for the 
production of farnesyl-PP and geranylgeranyl-PP that induces respectively farnesylation and 
geranylgeranylation of small GTPase. 
The fifth enzyme of the mevalonate pathway is pyrophosphomevalonate decarboxylase or 
diphosphomevalonate decarboxylase (EC 4.1.1.33). It converts mevalonate-5-pyrophosphate into 
isopentenyl-5-pyrophosphate (IPP), the final product of mevalonate pathway and the starting substrate 
for successive biosyntheticals reactions, especially cholesterol and isoprenoid production. This enzyme 
performs two key reactions: firstly, it phosphorylates mevalonate-5-pyrophosphate generating  
an intermediate product that, secondly, it is dephosphorylated and decarboxylated, obtaining thus IPP as 
a final product (Figure 1a, 5). 
The mevalonate pathway, as described above, generates a key intermediate for cholesterol production, 
a fundamental constituent of cell membranes. Moreover, cholesterol is also converted to steroid hormones, 
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regulating different cellular pathways, vitamin D and bile acid production (Figure 1b). IPP is the first 
step also in other, non-cholesterol, reactions; it is important for the production of farnesyl-pyrophosphate 
(FPP). FPP is converted in dolichols, used to assemble carbohydrate chains in glycoproteins, or in 
ubiquinones (or coenzyme Q10), electron transporters in mitochondria; or it is used to farnesylate or 
geranylate proteins, thus targeting them to cell membranes (Figure 1c). In summary, the mevalonate 
pathway is responsible for numerous cellular processes and the key enzymes described above undergo 
different regulation to maintain a constant supply of IPP. 
2. Exogenous Mevalonate Pathway Blockade 
The principal compounds that induce exogenous mevalonate pathway blockade are the statins, which 
are a class of compounds that act as competitive inhibitors of 3-hydroxy-3-methylglutaryl coenzyme-A 
(HMG-CoA) reductase, a key enzyme of the mevalonate pathway, which converts HMG-CoA into 
mevalonic acid. Statins, in general, are able to bind to a portion of HMG-CoA binding site, thus blocking 
the access of this substrate to the active site of the enzyme; effectively reducing the rate of mevalonate 
productions [9,10]. 
In 1976 Endo and coauthors discovered the first statin, isolated from Penicillium citrinium [11]. 
Subsequently, over the last two decades, several statins have been identified and classified in several 
ways. The most commonly used classification divides them into statins produced by fungi (such as 
Lovastatin, Simvastatin) and statins synthetically made (such as Atorvastatin, Fluvastatin). 
All statins share a conserved HMG-like moiety covalently linked to a more or less extended 
hydrophobic group. 
By blocking HMG-CoA reductase, statins induce a decrease in cholesterol level and simultaneously 
other by-products of the mevalonate pathway such as farnesyl pyrophosphate (FPP), geranylgeranyl 
pyrophosphate (GGPP), dolichols and coenzyme Q10 [12,13]. As reviewed in Winter-Vann and Casey 
(2005), inhibition of HMG-CoA reductase has a pleiotropic effect, due to the different affinities of key 
enzymes in the mevalonate pathway. FPP, the main metabolite in this pathway, could be converted to 
cholesterol through squalene synthase and this enzyme has a Km for the substrate of about 2 μM.  
GGPP synthase, instead, could convert FPP to GGPP, with a Km of 1 μM; GGPP is attached to different 
proteins (the majority of which pertain to the Rab family) to ensure their correct localization. On the 
other hand, protein farnesyl trasferase (FTase) uses FPP to attach a farnesyl group to specific proteins, 
such as the family of small GTPase proteins (Ras and Rho GTPases), with a Km of 5 nM. Therefore, 
inhibition of HMG-CoA reductase lowers FPP levels and the first consequence is a reduction in 
cholesterol levels; following that, GGPP levels are reduced, causing mislocalization and loss of activity 
of specific proteins. Instead, due to the high affinity of FTase towards FPP, farnesylation levels of key 
cellular enzymes remain stable [14]. 
Indeed, a widely adopted view considers the pleiotropic effects of statins independent of lowering 
cholesterol levels, but rather connected to a lack of these prenylated proteins [12]. In the last few years 
there has been an increase in interest of these pleiotropic effects, because of their possible main 
responsibility for statin anti-cancer and immunomodulatory effects [15–18]. 
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For all these reasons, the role of statins are debatable, and there are many studies describing statins 
as drugs for treatment of a variety of disease such as hypercholesterolemia, cancer, cardiovascular 
diseases, inflammatory diseases [19–24]. 
Furthermore, statins are used as a pharmacological compound to biochemically reproduce some 
features of Mevalonate Kinase Deficiency (MKD)—a pathology characterized by a defect in a key 
enzyme of mevalonate pathway [13,25,26]. In some studies, mevalonate pathway blockade, obtained in 
neuronal and monocytic cell lines by statin (Lovastatin) administration, induces an increase of apoptosis 
correlated to mitochondrial damage [27–29]. 
Also, Van der Burgh and co-workers have recently demonstrated that mevalonate pathway blockade, 
obtained in monocytic cell line by statin (Simvastatin) administration, produces mitochondrial damage 
and autophagy impairment, related to a decrease in protein prenylation levels [25,30]. 
2.1. Mitochondrial Dysfunction and Statin 
Mevalonate pathway blockade, obtained by treatment with statins, has been linked to mitochondrial 
dysfunction, specifically by lowering mitochondrial membrane potential and increasing release of  
pro-apoptotic factors. 
Usually, mitochondrial dysfunction is associated with intrinsic apoptosis, also known as the 
mitochondrial apoptotic pathway. This pathway is characterized by activation of caspase-9 and -3,  
and inhibition or activation of anti- or pro-apoptotic Bcl-2 family members. Furthermore, mitochondrial 
membrane potential decreases, causing release of pro-apoptotic factors, oxidative stress and then  
cell death [31]. 
In a biochemical MKD model, obtained by Lovastatin treatment in neuroblastoma cell lines, we 
observed mitochondrial dysfunction correlated to increased intrinsic apoptosis, also confirmed by 
activation of caspase-3 and -9 [27,28]; furthermore, in monocyte cell lines, we observed a similar 
increase in oxidative stress [29]. 
Mitochondrial dysfunction, caused by statins, could be related to oxidative stress, shortage of 
prenylated proteins or both. In fact, it was observed that the block of mevalonate pathway, obtained by 
statin (Simvastin) treatment in endothelial cancer cell lines, resulted in G1 cell cycle arrest, apoptosis, 
DNA damage and cellular stress [32]. 
Another study showed that simvastatin, in lung cancer cells, inhibited the proliferation and 
significantly increased oxidative stress, in particular augmenting reactive oxygen species (ROS) 
production and the activity of total superoxide dismutase (SOD) and in particular the mitochondrial 
form, superoxide dismutase 2 (SOD2) [33]. 
Strong oxidative stress, which induces mitochondrial dysfunction, could be due to the action of statins 
on the mevalonate pathway, decreasing coenzyme Q10 and dolichol levels, considered as anti-oxidants 
defense systems. 
Coenzyme Q10 is a product of the mevalonate pathway and is an important electron transporter of 
the mitochondrial respiratory chain. A decrease in coenzyme Q10 levels, caused by mevalonate pathway 
blockade, could result in an abnormal mitochondrial respiratory function causing mitochondrial and 
oxidative damage [34]. 
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Dolichol, a polyprenol compound, is an important free-radical scavenger in cell membranes [35]. 
Ciosek and co-workers observed a significant decrease in dolichol levels after Lovastatin administration 
in in vivo models [36]; a lack of this compound might cause oxidative stress and mitochondrial  
damage [13,37]. 
Nevertheless, mitochondrial dysfunction caused by statins could also be related to a decrease in 
prenylated protein levels; indeed, statins treatment could lead to a reduction in cholesterol level, and also 
in farnesyl pyrophosphate (FPP) and in geranylgeranyl pyrophosphate (GGPP). Xia and co-workers have 
demonstrated that apoptosis induced by Lovastatin treatment, in human AML cells is connected to a 
decrease in GGPP and, to a lesser extent, related to a FPP decrease [38]. 
Agarwal and co-workers also observed the close correlation between decrease in prenylated proteins 
levels, apoptosis and mitochondrial damage in Lovastatin-treated colon cancer cells. The treatment 
caused a decrease in expression of anti-apoptotic protein Bcl-2 and an increase of pro-apoptotic protein 
such as Bax; the subsequent addition of GGPP prevented Lovastatin apoptosis, confirming a key role of 
prenylated proteins levels [39]. 
Recently, Van der Burgh and co-workers have demonstrated that, in simvastatin-treated cells, 
mitochondria clearance is reduced, with lower oxygen consumption and glycolysis rate. These conditions 
suggested that accumulation of damaged mitochondria could be the trigger for NACHT, LRR and PYD 
domains-containing protein 3 (NALP3) inflammasome activation. The authors also speculate that 
prenylated proteins could be the main mediators of statin adverse effects [25,30]. 
Further confirmations that statins treatment could impair mitochondrial activity come from two recent 
studies done using a completely different model, C. elegans. In the first paper, the authors show that 
animals resistant to statin treatment have an increased mitochondrial unfolded protein response (UPRmt) 
which, they speculate, could lower protein turnover and thus lessening the need for protein prenylation [40]. 
In the second paper, the authors demonstrate that statin abrogates the C. elegans ability to sense 
mitochondrial damage and that this ability could be partially rescued through GGPP subministration [41]. 
Taken together, these results demonstrate once more the key role of protein prenylation in  
mitochondrial homeostasis. 
A mitochondrial-specific effect of statin, probably mediated through lowering prenylated proteins, 
suggests that this class of compound could be considered as anti-cancer drugs. However, further studies 
are necessary to completely clarify the variety of effects of these drugs and at present, only hypotheses 
have been raised to explain actions of statins on cellular survival. 
2.2. Autophagy and Statins 
Mevalonate pathway blockade has been linked to defective autophagy, possibly causing inflammasome 
activation and subsequent cell death. Autophagy (macroautophagy) is the main catabolic mechanism 
involved in the turnover of cytoplasmic components and selective removal of damaged or redundant 
organelles (such as mitochondria, peroxisomes and endoplasmic reticulum), through the lysosome 
machinery. Initial steps include the formation of phagophore or pre-autophagosome, an isolated 
membrane able to elongate and forming the autophagosome, a double-membrane compartment that 
sequesters the cytoplasmic materials. Subsequently, the fusion of autophagosome with lysosome forms 
the autolysosome, where the captured material is degraded [42] (Figure 2). 
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Figure 2. Schematic representation of macroautophagy mechanism and its main actors. 
Macroautophagy delivers cellular components and damaged or redundant organelles (such as 
mitochondria), to the lysosome through the intermediary of a double membrane-bound vesicle, 
referred to as an autophagosome. Autophagy is initiated by the formation of the isolation 
membrane that induces the formation of autophagosome. Subsequently, the autophagosome 
fuses with the lysosome to form an autolysosome. Finally all the material is degraded in the 
autophagolysosome and recycled. The p62 protein interacts with damaged proteins in the 
cells, and the complexes are then selectively tied to the autophagosome through LC3-II. 
Rabs, Rheb and RalB are autophagy-related protein important for the regulation of 
macroautophagy mechanism. 
Autophagy involves numerous molecular mediators called autophagy-related (ATG) proteins; among 
these, prenylation of proteins appears to be one of the key regulation mechanisms [43]. Specifically, 
different small GTPase are indicated as ATG proteins: Rabs, Rheb, RalB. Rabs are crucial proteins for 
developing subdomains on membranes to facilitate maturation; recent studies have shown that some 
Rabs are essential for autophagy. The best known Rabs at the present time are: Rab1, able to regulate 
the autophagosome formation; Rab5, an early endosome protein, responsible for autophagosome membrane 
elongation and autophagosome formation, regulating Beclin1-Vps34-Atg6 class III PI3-kinase complex; 
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Rab7, a late endosome protein, responsible for autophagosome maturation, promoting the microtubule 
plus-end-directed transport and facilitating fusion of autophagosome with lysosome; Rab24, normally 
present in reticular distribution around the nucleus, is important for autophagosome maturation;  
Rab32, generally present in mitochondria, regulates the membrane trafficking, and is required for 
autophagosome formation; Rab33 modulates autophagosome formation [44,45] (Figure 2). 
Ras homology enriched in brain (Rheb) directly binds and selectively activates the multiprotein 
complex 1 of mammalian target of rapamycin (mTORC1) [46] which is composed of mTOR, a negative 
regulator of autophagy, and mLST8 [47,48]. mTOR activity inhibits mammalian autophagy and indeed 
a recent study demonstrated that autophagy impairment is correlated to mTORC1 hyperactivation in  
β-cell [49] (Figure 2). 
RalB localizes in nascent autophagosome and is activated due to nutrient deprivation and, thanks  
to the binding to its effector Exo84, induces the assembly of active Beclin1-VPS34 and ULK1.  
The resulting complex induces the isolation of pre-autophagosomal membrane and maturation of 
autophagosomes [50,51] (Figure 2). 
All these proteins require prenylation for their activation, either farnesylated or geranylgeranylated; 
indeed statins, blocking the mevalonate pathway and causing a decrease in prenylated proteins  
levels, could play a regulatory role in autophagy. Nevertheless, the statin effects in autophagy remain 
poorly understood. 
Recently, Van der Burgh and co-workers have observed defective autophagy in statin-treated 
monocytes, correlated to damaged mitochondria and NALP3 inflammasome activation [25]. The same 
authors have subsequently demonstrated that statin treatment increases levels of unprenylated RhoA, 
which in turn activates protein kinase B (PKB) possibly playing a role in statin-induced autophagy 
blockade [30]. 
On the contrary, other studies show that treatment with statins induces an increase in autophagy 
levels, and for this reason, statins could be considered as anti-cancer drugs. Indeed, a study showed that 
statins, such as Cerivastatin, Pitavastatin and Fluvastatin, are the most potent autophagy inducing agents 
in human cancer cells; the authors, however, did not analyze levels of p62, thus the possibility that 
autophagy is increased but subsequentrly blocked was not examined [52]. 
Another study demonstrated that statin induces autophagy through depleting cellular levels of 
geranylgeranyl diphosphonate (GGPP), independently of the decreased activity in two major small G 
proteins, Rheb and Ras [53]. However, the authors did not examine all autophagic pathways, thus the 
observations are not conclusive and further investigations are needed. 
Lastly, Wei and co-workers observed that simvastatin inhibits the Rac1-mTOR pathway and thereby 
increases autophagy, in coronary arterial myocytes [54]. 
All these results show that the role of statin in autophagy is related to GGPP and prenylated proteins 
levels, thus being important actors in this mechanism. Indeed, cellular differences in GGPP and 
prenylated proteins levels could explain the contradictory findings in the studies described above. 
However, further studies are necessary to clarify the mechanism of action and the molecular targets 
involved in statin-modulated autophagy. 
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3. Endogenous Mevalonate Pathway Blockade 
The mevalonate pathway could also be blocked by enzymatic defects due to mutations in genes 
involved in this pathway. In particular, a rare disease involving mutations on MVK gene (12q24.11) has 
been described: Mevalonate Kinase Deficiency (MKD). Currently, 82 mutations of the MVK gene have 
been reported in the Human Gene Mutation Database [55]. 
MKD possesses two distinct phenotypes: a milder one, also called Hyper IgD Syndrome (HIDS; 
OMIM#260920), in which the patients suffer recurrent fevers, have skin rashes, hepatosplenomegalia 
and generally a sustained inflammatory response; and a severe, rarer, one, called Mevalonic Aciduria 
(MA; OMIM #610377), characterized by the involvement of the Central Nervous System, with cerebellar 
ataxia, psychomotor retardation and also, as in HIDS, recurrent fever attacks [56]. 
Residual MVK enzymatic activity marks the boundary between HIDS and MA, with MA patients 
having less than 1% activity, while HIDS between 1% and 7% of activity [57]. Initially, disease 
pathogenesis was thought to derive from low cholesterol levels, being MVK a central enzyme in the 
mevalonate pathway. However, patients, either with HIDS or MA, showed normal cholesterol levels, 
probably due to dietary intake. Subsequently, accumulation of Mevalonic acid was indicated as 
responsible for the MKD phenotype. Still, a small clinical trial, involving two MA patients, using statin 
(Lovastatin) to reduce Mevalonic acid, resulted in worsening of the symptoms [58]; on the contrary, 
Simvastatin appeared to be beneficial for treating HIDS patients [56]. Thus, the hypothesis pointing to 
Mevalonic acid levels as causative for MKD does not explain completely the disease’s manifestations. 
Celec and Behuliak in 2008 hypothesized that MVK dysfunctions could diminish non-steroid 
isoprenoids, causing oxidative stress and ultimately leading to chronic hyperinflammation [13]. 
The shortage of isoprenoids, correlated to a severe reduction in protein prenylation, in particular of 
geranylgeranyl pyrophosphate (GGPP), has been linked with the activation of caspase-1 and thereby 
with the production of IL-1β [59,60]. 
In particular, the IL-1 family is strongly supposed to play a fundamental role in MKD inflammatory 
processes, indeed, several biological therapies have successfully targeted these molecules [61–63]. 
In a previous work it has been shown that, in monocytes from MKD patients, a key component of the 
inflammation machinery is NACHT, LRR and PYD domains-containing protein 3 (NALP3) [64]; 
NALP3 interacts with another protein, pyrin domain (PYD) of apoptosis-associated speck-like protein 
containing a CARD domain (ASC), constituting the inflammasome platform. The CARD domain 
recruits pro-caspase-1, which self-cleaves into active caspase-1 and then converts pro-IL-1β to active 
IL-1β, activating one of the main pathways of inflammation [65,66]. 
However it remains an open question how isoprenoid shortage, as in MKD and in presence of the 
biochemical block, activates NALP3 and the inflammasome pathway. 
Recently Van der Burgh and co-workers have demonstrated that, in MKD patients’ cells and in  
statin-treated monocytes, autophagy is impaired and specifically mitochondria clearance is slowed, 
suggesting that accumulation of damaged mitochondria could be the trigger to NALP3 inflammasome 
activation [25]. The same group has recently reported that statin treatment increases levels of unprenylated 
Ras homolog gene family member A (RhoA), which in turn activates PKB, representing then the 
hypothetical starting point for autophagy. The authors also demonstrated that levels of unprenylated 
RhoA correlate with IL-1b release, thus partially confirming this hypothetical link [25,30]. 
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4. Autophagy, Inflammation and Damaged Mitochondria 
An emerging concept in recent years tightly associates autophagy with inflammation regulation 
mechanisms. Autophagy can regulate different aspects of the immune response: it is involved in the 
degradation of bacteria/virus engulfed by the cell, it regulates Pattern Recognition Receptors (PRRs) and 
can act as their effector, it can process Antigens for MHC presentation and finally autophagy can regulate 
inflammasome activation and secretion of different cytokines [67]. The first three mechanisms have been 
extensively described by Deretic (2013) [68], and will be briefly discussed here. 
Autophagy can be envisaged as a mechanism to clear the cytosol from invading intracellular pathogens, 
either bacteria or viruses, which are engulfed in autophagic membranes and targeted to lysosomes to be 
degraded. This process is facilitated by sequestosome 1/p62-like receptors (SLRs) that recognize 
pathogens and facilitate their encasement in autophagosomes, possessing an LC3 interacting region. 
Furthermore, autophagy could be an effector for PRRs, degrading targets marked by toll-like 
receptors (TLRs) or it can help in delivering ligands to TLRs, as for TLR7 [68]. 
Antigen processing for MHC II presentation represents another important mechanism regulated  
by autophagy. Indeed, autophagy is crucial for viral immunosurvelliance and is also inhibited by HIV-1 
by upregulating mTOR in dendritic cells [69,70]. Moreover, autophagy is required for positive selection 
of naïve T cells in thymus, whereas knocking-out key autophagy proteins results in autoimmune 
syndromes [71]. 
How autophagy regulates inflammasome activation is currently a subject of numerous studies and a 
general consensus has not been yet reached. However, two hypotheses are at the moment explored:  
a first one suggesting that autophagy regulates processing of IL-1b and other pro-inflammatory 
molecules; the second proposing that autophagy removes damaged mitochondria, thus dampening 
NALP3 activation. It is possible that those two processes are not mutually exclusive and act in parallel 
to maintain the inflammatory status in “inactive” condition. 
Direct regulation of IL-1b processing by inflammasomes has been demonstrated in macrophages and 
in vivo where treatment with rapamycin (autophagy inducer) decreases its secreted and circulating  
levels [72]. Further confirmation came from the work of Shi and co-authors (2012), in which they 
demonstrate how inflammasome activation induces autophagy and autophagosomes formation 
containing inflammasomes components such as ASC or absent in melanoma 2 (AIM2), in a self-limiting 
process. IL-1b does not possess a “canonical” secretory signature and it is translated in the cytosol, via 
polyribosomes linked to the cytoskeleton [73–75]. Later it was demonstrated that secretion of IL-1b is 
dependent on its localization in lysosome-associated vesicles and agents that regulates autophagy can 
modulate its release [72,76]. These works clearly show the regulation of IL-1b processing by autophagy. 
Other studies put autophagy upstream of inflammasome activation. Reactive oxygen species (ROS) 
can activate NALP3 inflammasome and damaged mitochondria are the main source for ROS. 
Mitophagy, a specialized form of autophagy, constantly removes damaged mitochondria, thus lowering 
ROS levels. If cells are challenged with 3-methyladenine, a blocker of mitophagy, NALP3 activation is 
increased and redistributed near mitochondria-ER contact points, working as a sensor for mitochondrial 
damage [77]. 
Moreover, mitochondrial DNA (mtDNA) can work as NALP3 activation inducer, thus sensing 
mitochondrial damage and 3-MA could increase NALP3 activation caused by mtDNA [78,79].  
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These data show a possible pipeline: decreased mitophagy leading to increased ROS and mtDNA in 
cytosol, leading to increased NALP3 activation. 
The two mechanisms described above are not necessarily self-exclusive. It is then possible that 
autophagy machinery collaborates in dampening inflammation and a disturbance in mitochondria 
homeostasis could lead to exacerbating inflammation. 
In MKD is it then possible that a disturbance in autophagy mechanisms causes damage in 
mitochondria, impairing their recycling and thus increasing ROS levels; this, in turn, increases activation 
of inflammation. This chain of events still remains to be verified; however exploring this mechanism 
could represent a novel strategy to fight this debilitating disease. 
5. Conclusive Remarks 
MKD is an orphan drug disease, so many efforts are being made in search of potential targets for 
novel treatments tailored to prevent, or at least to diminish, apoptosis in MKD patients. Several studies 
reported in vitro administration of natural and synthetic isoprenoids to restore the mevalonate pathway 
in cell cultures (both models and patients’ derived monocytes) treated with statins to biochemically 
mimic the genetic defect. 
As described above, a possible link exists between defective protein prenylation and mitochondrial 
dysfunction, supposedly made by autophagy (Figure 3). 
Furthermore, it remains to be determined how autophagy is impaired in MKD. Protein prenylation 
seems to be one of the regulation mechanisms involved in autophagy. Compounds able to restore protein 
prenylation could be considered as potential therapy to tackle MKD; unfortunatly such compounds are 
at the present time, not actively researched. Other strategies, such as modulation of farnesyl protein 
transferase could be exploited to fight MKD. 
For all these reasons, our review aimed at recalling the attention of the scientific community on 
another possible mechanism at the basis of MKD pathogenesis, and intends to point out that autophagy 
should be considered when trying to design novel therapeutic strategies to fight cell death in MKD patients. 
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Figure 3. Schematic representation of a possibile link between defective protein prenylation, mitochondrial dysfunction and autophagy. 
Mevalonate Kinase Deficiency is characterized by a block of the mevalonate pathway induces by mutation in a gene that encodes for Mevalonate 
Kinase. Blockade of the mevalonate pathway induces decrease in protein prenylation that could alter the macroautophagy mechanism and in 
particular mitochondrial degradation and recycling. Accumulation of damaged mitochondria induces ROS production and mtDNA release.  
All these events are important for the activation of NALP3 inflammasome that cleaves and activates IL-1b. 
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